What type of study is this?

This is a Quantitative Study study.

September 17, 2025

Assessment of the feasibility and optimal dosing of human abdominal deuterium metabolic imaging (DMI) at 3T

Key Points

Abdominal DMI is feasible at 3T, with effective imaging recorded in healthy volunteers, and demonstrating promising signal timecourses.
The study found that reducing the glucose dose by one-third did not compromise measurement reliability, decreasing overall scan costs.
Optimizations in the RF coil setup helped minimize unwanted gastric signals while ensuring consistent hepatic and renal timecourses across varying doses.
These findings establish a foundational understanding for future clinical applications of abdominal DMI in metabolic imaging.

Abstract

Motivation: DMI is a promising non-invasive metabolic imaging tool, but clinical field strength and abdominal spectroscopy pose significant technical challenges. Goal(s): To adapt abdominal DMI to clinical settings by optimizing the RF coil setup, 6,6'-²H2glucose dose, and data processing, establishing the basis for future clinical applications. Approach: 5 healthy volunteers underwent imaging on 2-3 occasions with varying 6,6'-²H2glucose doses. Results: Unwanted gastric signal was minimized with this setup. Hepatic and renal timecourses were consistent across doses, although decreased doses slightly lowered quantitative values. Abdominal DMI is feasible at 3T, and the 6,6'-²H2glucose dose can be reduced by one-third without affecting measurement reliability. Impact: This study shows the feasibility of human abdominal DMI at clinical field strengths. It demonstrates signal timecourses within the healthy kidney and liver as a reference for future clinical studies. In addition a dose reduction lowers the DMI scan costs.

Mark Helpful

Bookmark

Relay